Stock Price & Analysis

Based on the provided data, here's a concise analysis of TAK stock:

Recent Performance & Business Updates:

• Takeda recently raised its FY2024 guidance, projecting increased revenue and core operating profit
• The company announced a JPY 100 billion share buyback program, demonstrating confidence in financial outlook
• Leadership transition announced: CEO Christophe Weber will retire in June 2026, with Julie Kim set to succeed

Financial Highlights:

• Revenue grew 9.8% year-over-year to ¥3528.2B for the nine months ending December 31, 2024
• Core operating profit margin improved to 28.5%
• Growth & Launch products contributed 47% of total revenue with notable growth in key products

Positive Catalysts:

• Recent EMA approval for Takhzyro two mL pre-filled pen option
• Strong performance in plasma-derived therapies with immunoglobulin growth of 11.9%
• Raised free cash flow guidance by ¥150 billion to ¥550-650 billion range

Risk Factors:

• Potential biosimilar competition for key products
• IRA pricing negotiations impact
• ENTYVIO's adjusted growth trajectory concerns

Based on the recent financial performance, strategic initiatives, and positive regulatory developments, TAK stock appears to be a BUY at current levels. The company's improved guidance, share buyback program, and strong product pipeline provide multiple catalysts for growth.

Based on the recent earnings call and financial data, here's the 2025 price prediction for TAK stock in three sentences:

TAK stock is projected to reach $18-20 by end of 2025, driven by strong revenue growth outlook with low-single-digit increase in core revenue and operating profit. The positive momentum is supported by the company's robust product performance, including 14.6% growth in Growth & Launch products, improved core operating margin of 28.5%, and strategic initiatives like the JPY 100 billion share buyback program. However, potential headwinds from VYVANSE genericization and IRA pricing pressures could create some volatility, though management remains confident in sustaining revenue and bottom-line growth through 2025.

The S1 support level for TAK Stock is $14.07 ,The R1 resistant level for TAK Stock is $14.95.

As of the end of day on 2025-03-06, the price of TAK Stock was $14.92.

The target price for TAK Stock according to analyst rating is 14.80, with the highest price target at 14.80 and the lowest at 14.80. Analysts have a Moderate Buy rating on TAK Stock overall.

The market cap of TAK is $23.9B.

Based on the provided data and recent earnings reports, here's a concise analysis of TAK's valuation:

Financial Performance:

• Strong revenue growth of 9.8% year-on-year to ¥3.5 trillion for first nine months of FY2024
• Core operating profit margin improved to 28.5%, showing operational efficiency
• Operating cash flow reached ¥835 billion, up 90.8%

Growth Drivers:

• Growth & Launch products contributed 47% of total revenue with notable performers:
  • TAKHZYRO: 16.4% CER growth
  • ENTYVIO: 6.6% CER growth (despite pricing adjustments)
  • Plasma therapies: Immunoglobulin up 11.9%, Albumin up 2.2%

Forward Outlook:

• Raised FY2024 guidance:
  • Revenue: ¥4.59 trillion
  • Core operating profit: ¥1.15 trillion
  • Core EPS: ¥507
• Announced ¥100 billion share buyback program
• New leadership transition planned with Julie Kim succeeding CEO Christophe Weber in 2026

Conclusion: TAK appears fairly valued considering:

1. Strong operational performance and margin improvements
2. Raised guidance and confidence in 2025 growth
3. Strategic initiatives including share buyback
4. Solid product portfolio performance
5. Healthy cash flow generation

However, investors should monitor risks including:

• Potential biosimilar competition for ENTYVIO (2030-2032)
• IRA pricing pressure impacts
• Leadership transition execution

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Based on the provided data and analysis of Takeda Pharmaceutical (TAK), here is the 2030 price prediction:

TAK stock is projected to reach $22-25 by 2030, driven by strong pipeline development and operational efficiency improvements. The company's strategic focus on Growth & Launch products, which currently contribute 47% of revenue, coupled with patent protection for key products like ENTYVIO until 2030-2032, supports sustained growth potential. The recent leadership transition and operational improvements, including a 28.5% core operating profit margin, indicate robust long-term business fundamentals.

TAK has a total of 49281 employees.